GlassScriptPhysician profile
Nonyelum E Ejieke
NPI 1578623856
$1,428.16
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.48 · 2022: $275 · 2023: $600 · 2024: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,015 · Education: $38.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,015.30 |
| Education | $38.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $365.23 | 2019-2024 | Enbrel, Tavneos, Otezla |
| Aurinia Pharma U.S., INC. | $160.61 | 2022-2023 | Lupkynis |
| Janssen Biotech, INC. | $154.97 | 2019-2024 | Tremfya |
| Pfizer INC. | $140.68 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $140.22 | 2022-2024 | |
| Abbvie INC. | $108.55 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $66.02 | 2019-2022 | |
| Sobi, INC | $63.04 | 2023-2024 | |
| Ucb, INC. | $57.72 | 2022-2024 | Cimzia |
| Glaxosmithkline, LLC. | $45.42 | 2023-2024 | Benlysta, Nucala |
| Radius Health, INC. | $25.04 | 2024 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.24 | 2023 | Ofev |
| Akebia Therapeutics INC | $22.53 | 2022 | |
| Daiichi Sankyo INC. | $19.72 | 2023 | Injectafer |
| Fresenius USA Marketing, INC. | $17.25 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $16.92 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nonyelum Ejieke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.